Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Pharmacol
Auteurs principaux: Ermisch, Michael, Bucsics, Anna, Vella Bonanno, Patricia, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Fürst, Jurij, Garuolienė, Kristina, van der Graaff, Martin, Gulbinovič, Jolanta, Haycox, Alan, Jones, Jan, Joppi, Roberta, Laius, Ott, Langner, Irene, Martin, Antony P., Markovic-Pekovic, Vanda, McCullagh, Laura, Magnusson, Einar, Nilsen, Ellen, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Sauermann, Robert, Schuurman, Ad, Ramos, Ricardo, Vlahovic-Palcevski, Vera, Zara, Corinne, Godman, Brian
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2016
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039228/
https://ncbi.nlm.nih.gov/pubmed/27733828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00305
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires